Zinzino announced its preliminary sales results for the third quarter of 2026. Group revenue during the quarter grew 18% year-over-year to $31 million. Zinzino’s sales markets increased 15% year-over-year, totaling approximately $30 million. Faun Pharma’s external sales totaled $64,000. Accumulated revenue for the first nine months of 2026 grew by 21% year-over-year to $277 million.
South America, which includes Peru and Colombia, saw the strongest third quarter growth rate at 189%, when compared to the previous year’s quarter. North America (Canada, US and Mexico) reported third quarter growth of 55%, with Asia-Pacific (Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines and South Korea) following at 48% year-over-year increase.
